Novel Technologies For In Vivo Imaging (R33)

The summary for the Novel Technologies For In Vivo Imaging (R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Technologies For In Vivo Imaging (R33): Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R33 (Phase II, Developmental) grant applications from applicant organizations that propose the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This FOA is primarily intended to facilitate the development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and/or treatment of various diseases. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -The anticipated number of awards is not known. -This FOA will utilize the NIH R33 (Phase II, Developmental) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-06-398, that solicits applications using the Phased Innovation R21/R33 grant mechanism. The proposed Phase II study should be designed to test whether application of feasible technology or technologies will provide clinical benefit to a defined set of cancer patients. -The total project period for an R33 application submitted in response to this FOA may not exceed 3 years. Although the R33 grant application has no official budgetary limit, applications requesting $500,000 or more in direct costs in any single year of the grant period require prior approval from the NIH 6 weeks before submission. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Eligible organizations: For-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of local governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; faith-based or community-based organizations; Indian/Native American Tribal Governments (Federally Recognized); Indian/Native American Tribal Governments (Other than Federally Recognized); and Indian/Native American Tribally Designated Organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research; any eligible PD/PI is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.